IDS Events

May 1-2nd, an audience of 275 doctors, researchers, pharmacists, advanced-practice providers and medical trainees gathered to hear form 48 speakers in shared recognition of the importance of working to mitigate serious complications in immunocompromised individuals. The international event included participants from over one hundred institutions, thirteen countries, and six continents. The symposium addressed COVID-19, Cytomegalovirus and Human Herpesvirus-6, Fungal Disease, Immunotherapy, Respiratory Virus Disease, Antimicrobial Resistance and Microbiome, and Vaccines. Speakers also discussed case presentation and round table discussions with audience participation within these subject areas. Seventy-one trainees were able to attend the symposium as a part of the travel stiped program. 

Introduction

Co-chairs: Michael Boeckh, Catherine Liu, Joshua Schiffer
Fred Hutchinson Cancer Center, University of Washington

Keynote Address  

Introduction: Michael Boeckh, Fred Hutchinson Cancer Center, University of Washington

COVID-19 Vaccines in Immunocompromised Patients
Lindsey Baden, Brigham and Women's Hospital, Dana Farber Cancer Institute, Harvard University

COVID-19 

Chairs: Catherine Liu, Fred Hutchinson Cancer Center, University of Washington
Helen Chu, University of Washington

COVID-19 in Immunocompromised Hosts: Outcomes and Therapeutic Management Strategies
Ghady Haidar, University of Pittsburgh

Case Presentation and Round Table Discussion (with audience response system): Challenges in Management of COVID-19 in Immunocompromised Hosts— Protracted Infection and Persistent Viral Shedding
Discussants:
Catherine Liu, Fred Hutchinson Cancer Center, University of Washington
Helen Chu, University of Washington
Ghady Haidar, University of Pittsburgh
Madeleine Heldman, Duke University
Mini Kamboj, Memorial Sloan Kettering

Cytomegalovirus and Human Herpesvirus-6 — New Approaches

Chairs: Ajit Limaye, University of Washington
Danniel Zamora, Fred Hutchinson Cancer Center, University of Washington

CMV After Hematopoietic Cell Transplantation: New Drugs and Immune Monitoring
Roy Chemaly, MD Anderson Cancer Center

CMV in Solid Organ Transplant Recipients: New Drugs and Immune Monitoring 
Joanna Schaenman, University of California Los Angeles

HHV-6 Pulmonary Disease: What is the Evidence?
Joshua Hill, Fred Hutchinson Cancer Center, University of Washington

Case Presentation and Round Table Discussion (with audience response system): A Challenging Case of Resistant CMV Infection
Case Presenter: Danniel Zamora, Fred Hutchinson Cancer Center, University of Washington

Discussants:
Joshua Hill, Fred Hutchinson Cancer Center, University of Washington
Genovefa Papanicolaou, Memorial Sloan Kettering Cancer Center
Michael Boeckh, Fred Hutchinson Cancer Center, University of Washington
Roy Chemaly, MD Anderson Cancer Center
Danniel Zamora, Fred Hutchinson Cancer Center, University of Washington
Ajit Limaye, University of Washington

Fungal Disease

Chairs: Monica Slavin, MacCallum Cancer Centre, Melbourne, Australia
Ricardo La Hoz, UT Southwestern Medical Center

New Antifungal Agents 
Dimitrios Kontoyiannis, MD Anderson Cancer Center

Case Presentation and Round Table Discussion (with audience response system): Controversies in Fungal Management (Mucor Therapy, Threshold for Proceeding to Transplantation)
Discussants:
David Fredricks, Fred Hutchinson Cancer Center, University of Washington
Monica Slavin, MacCallum Cancer Centre, Melbourne, Australia
Dimitrios Kontoyiannis, MD Anderson Cancer Center
Julian Lindsay, Fred Hutchinson Cancer Center
Ricardo La Hoz, UT Southwestern Medical Center

Immunotherapy

Chairs: Joshua Hill, Fred Hutchinson Cancer Center, University of Washington
Madeleine Heldman, Duke University

Best Trainee Abstract

Infections in CAR T-Cell Recipients
Muhammad Bilal Abid, Medical College of Wisconsin

Advances in Virus-Specific Immunotherapy
Genovefa Papanicolaou, Memorial Sloan Kettering Cancer Center

Keynote Address 

Introduction: Per Ljungman, Karolinska Institutet, Stockholm, Sweden

Respiratory Virus Vaccinations in Immunocompromised Hosts
Janet Englund, Seattle Children's Hospital, University of Washington

Respiratory Virus Disease

Chairs: Angela Campbell, Centers for Disease Control and Prevention
Per Ljungman, Karolinska Institutet, Stockholm, Sweden

Impact of Respiratory Viruses in Hematopoietic Cell Transplantation and Hematology/Oncology Patients During COVID-19 and Beyond
Alpana Waghmare, Seattle Children's Hospital,  University of Washington, Fred Hutchinson Cancer Center

Impact of Respiratory Viruses in Solid Organ Transplant Patients During COVID-19 and Beyond 
Lara Danziger-Isakov, Cincinnati Children’s Hospital Medical Center

Case Presentation and Round Table Discussion (with audience response system): To Delay or Not Delay Transplantation
Discussants:
Alpana Waghmare, Seattle Children's Hospital, University of Washington, Fred Hutchinson Cancer Center
Per Ljungman, Karolinska Institutet, Stockholm, Sweden
Angela Campbell, Centers for Disease Control and Prevention
Cynthia Fisher, University of Washington
Lara Danziger-Isakov, Cincinnati Children’s Hospital Medical Center
Michael Ison, National Institute of Allergy and Infectious Diseases

Antiviral Treatment (Including COVID-19)

Michael Ison, National Institute of Allergy and Infectious Diseases

Monoclonal Antibodies (Including COVID-19)
Jim Boonyaratanakornkit, Fred Hutchinson Cancer Center, University of Washington

Keynote Address

Introduction: David Fredricks, Fred Hutchinson Cancer Center, University of Washington

Advances in Fecal Microbiota Transplantation for the Eradication of Multidrug-Resistant Organisms and Treatment of Graft-Versus-Host Disease 
Julian Marchesi, Imperial College London, England

Antimicrobial Resistance and Microbiome

Chairs: David Fredricks, Fred Hutchinson Cancer Center, University of Washington
Stephanie Pouch, Emory University

Challenges and Opportunities for Management of Antimicrobial Resistance in the Immunocompromised Host
Judith Anesi, University of Pennsylvania

Phage Therapy for Multidrug-Resistant Organisms
Saima Aslam, University of California San Diego

Vaccines

Chairs: Sanjeet Dadwal, City of Hope
Upton D. Allen, University of Toronto, The Hospital for Sick Children

Progress in Herpesvirus Vaccines: Varicella-Zoster Virus and Cytomegalovirus
Mark Schleiss, University of Minnesota

How to Approach Hesitant Patients on Vaccination
Annika Hofstetter, Seattle Children’s Hospital, University of Washington

Vaccination: Special Considerations in Immunocompromised Hosts
Steve Pergam, Fred Hutchinson Cancer Center, University of Washington

Closing  |  Co-chairs: Michael Boeckh, Catherine Liu, Joshua Schiffer
Fred Hutchinson Cancer Center, University of Washington

On June 10-11, 2019 a diverse audience of more than 200 doctors, researchers, pharmacists, advanced-practice providers and medical trainees gathered together in shared recognition of the importance of working to mitigate serious complications in immunocompromised individuals. The event featured outstanding, internationally recognized experts in the field, representing more than 23 institutions, who spoke on topics including infections in solid organ transplant, hematopoietic cell transplant and oncology. The symposium addressed fungal disease, respiratory viruses, C. difficile, CMV, immunotherapy, the microbiome, and antimicrobial stewardship. Speakers covered controversies in the field through multiple panel discussions and a pro/con debate with audience response opportunities for an interactive two-day symposium. 

Event Schedule

Day 1 Introduction
Michael Boeckh | Fred Hutch, University of Washington                                                   

Keynote Address
Native Indigenous Protective Factors of the Microbiome Against Clostridium difficile
Casey Theriot | North Carolina State University  

Clostridium Difficile and the Microbiome

Chairs
David Fredricks | Fred Hutch, University of Washington
Steven Pergam | Fred Hutch, University of Washington

Pre-transplant Intestinal Microbial Diversity Predicts Critical Illness After Hematopoietic Cell Transplantation
Fatima Adhi | Cleveland Clinic

Clostridium difficile and Fecal Microbiota Transplantation   
Krishna Rao | University of Michigan

Pro/Con Debate: What is the Optimal Approach for Detection of Clostridium difficile Infection — Especially in Immunocompromised Patients? 

Moderators:

David Fredricks | Fred Hutch, University of Washington
Steven Pergam | Fred Hutch, University of Washington

Debators:

Ferric Fang | University of Washington, Harborview Medical Center
Christopher Polage | Duke University

Cytomegalovirus (CMV)

Chairs:

Michael Boeckh | Fred Hutch, University of Washington
Ajit Limaye | University of Washington, Fred Hutch

Managing Cytomegalovirus After Hematopoietic Cell Transplantation
Genovefa Papanicolaou | Memorial Sloan Kettering Cancer Center

Managing Cytomegalovirus in Solid Organ Transplant Recipients
Nina Singh | University of Pittsburgh

Panel Discussion: Controversies in Cytomegalovirus Management

Case presenters: 

Camille Kotton | Massachusetts General Hospital
Sara Vora | Seattle Children’s Hospital

Moderators:

Michael Boeckh | Fred Hutch, University of Washington
Ajit Limaye | University of Washington, Fred Hutch

Panelists:

• Roy Chemaly | The University of Texas MD Anderson Cancer Center
• YaeJean Kim | Samsung Medical Center, Seoul, South Korea
• Francisco Marty | Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School
• Genovefa Papanicolaou | Memorial Sloan Kettering Cancer Center

Fungal Disease

Chairs:

Kieren Marr |Johns Hopkins University School of Medicine
Monica Slavin | University of Melbourne, National Centre for Infections in Cancer, Australia

A Single Center, 0pen-label Trial of Isavuconazole Prophylaxis Against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant 
Anat Stern, Memorial Sloan Kettering Cancer Center

New Antifungal Drugs
Kieren Marr | Johns Hopkins University School of Medicine

Fungal Diagnostics
John Perfect | Duke University

Panel Discussion: Controversies in Fungal Management                                                                               

Case presenters: Steven Pergam | Fred Hutch, University of Washington
Brian Fisher | Children's Hospital of Philadelphia

Moderators: 

Kieren Marr | Johns Hopkins University School of Medicine
Monica Slavin | University of Melbourne, National Centre for Infections in Cancer, Australia

Panelists:

• Sanjeet Dadwal, City of Hope
• Tobias Hohl, Memorial Sloan Kettering Cancer Center, Fred Hutchinson Cancer Research Center*
• Dimitrios Kontoyiannis, The University of Texas MD Anderson Cancer Center
• John Perfect, Duke University

Immunotherapy

Chairs:

Issam Raad | The University of Texas MD Anderson Cancer Center
Rebecca Gardner | Seattle Children’s Hospital

Infections in CAR T Cell Recipients
Joshua Hill | Fred Hutch, University of Washington

Infections Following Novel Immunotherapies
Mark Awad | Harvard Medical School, Dana-Farber Cancer Institute

Day 2
Keynote Address

Host Transcriptomics for Infectious Disease Diagnostics
Christopher Woods | Duke University

Respiratory Virus Disease

Chairs:

Per Ljungman | Karolinska University Hospital, Karolinska Institutet, Sweden
Angela J.P. Campbell |, Centers for Disease Control and Prevention

Respiratory Viral Infection Does Not Decrease Odds of Other Microbiologically Documented Infection in Febrile Neutropenia in Children with Cancer
William Otto | The Children's Hospital of Philadelphia

Hematopoietic Cell Transplantation Recipients
Alpana Waghmare | Seattle Children's Hospital, University of Washington, Fred Hutch

Solid Organ Transplantation Recipients
Cynthia Fisher | University of Washington, Fred Hutch

Antiviral Treatment in Solid Organ Transplantation Recipients
Michael Ison | Northwestern University

Antimicrobial Stewardship

Chairs:

Catherine Liu | Fred Hutch, University of Washington
Scott Weissman | Seattle Children’s Hospital

Keynote Address
Pros and Cons of Withdrawing Quinolone Prophylaxis for the Prevention of Neutropenic Fever
Monica Slavin | University of Melbourne, National Centre for Infections in Cancer, Australia

Challenges and Opportunities for Antimicrobial Stewardship and Infection Prevention in Pediatric Hematology-Oncology/Bone Marrow Transplantation
Joshua Wolf | St. Jude’s Children’s Hospital

Multi-Drug Resistant Gram-Negative Bacteria and Asymptomatic Bacteriuria in Solid Organ Transplant Recipients
Lilian Abbo | University of Miami

Management of Neutropenic Fever: Past, Present, and Future
Susan Seo | Memorial Sloan Kettering Cancer Center

Closing Remarks
Michael Boeckh, Fred Hutchinson Cancer Research Center, University of Washington

In September 2018, Fred Hutch hosted a two-day symposium highlighting research on interactions between the microbiome and cancer. Research is revealing that the microbiome can affect susceptibility to disease, including cancer. In addition, the microbiome is linked to the success of cancer therapies and the development of infectious complications. The symposium drew 115 attendees from the Hutch, the University of Washington and other Seattle research institutions, and featured 19 speakers, including keynoter Dr. Yasmine Belkaid, director of the Microbiome Program at the National Institute of Allergy and Infectious Diseases, in Bethesda, Maryland.

Day 1 Introduction

David Fredricks | Fred Hutch, University of Washington

Greeting
Geoffrey R. Hill | Fred Hutch

Therapeutics
Moderator
Mac Cheever | Fred Hutch; University of Washington

Commensal Microbiota and Anti-Tumor Immunity
Thomas F. Gajewski | University of Chicago

Development of Microbiome Drugs for Immune Related Disorders
David Cook | Seres Therapeutics

Diet
Moderator
William R. DePaolo | University of Washington

Diet, the Microbiome, and Colon Cancer Risk
Stephen J.D. O’Keefe | University of Pittsburgh; University of Stellenbosch, South Africa

Gut Microbial Metabolism of Dietary Phytochemicals and Impact on Cancer Risk
Johanna Lampe | Fred Hutch; University of Washington

Microbiome-Encoded Targets for the Prevention of Colorectal Cancer
Neelendu Dey | Fred Hutch; University of Washington

Hematopoietic Cell Transplant
Moderator
Steven Pergam | Fred Hutch; University of Washington

Microbiome Modulation of Intestinal Barrier Function
Robert Jenq | University of Texas MD Anderson Cancer Center

Dynamics of the Gut Microbiota after Hematopoietic Cell Transplantation
David Fredricks | Fred Hutch; University of Washington

MAIT Cell Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation
Cameron Turtle | Fred Hutch; University of Washington

Panel Discussion: The Next Generation of Research
Moderator

• David Fredricks | Fred Hutch; University of Washington

Panelists

• David Cook | Seres Therapeutics
• Neelendu Dey | Fred Hutch; University of Washington
• Robert Jenq | University of Texas MD Anderson Cancer Center
• Johanna Lampe | Fred Hutch; University of Washington
• Stephen O’Keefe | University of Pittsburgh; University of Stellenbosch, South Africa

Poster Session and Reception

Day 2 Introduction
Sujatha Srinivasan | Fred Hutch

Keynote Address
Control of Tissue Immunity and Repair by the Microbiota
Yasmine Belkaid | National Institutes of Health

Basic Sciences
Moderator
Nina Salama | Fred Hutch

Acquired Interbacterial Defense (AID) Systems Encoded by Members of the Highly-Abundant Order Bacteroidales
Benjamin Ross | University of Washington

Maternal Antibodies Regulate Neonatal Intestinal Homeostasis
Meghan Koch | Fred Hutch

Tumor Microbiota in the Progression and Treatment of Colorectal Cancer
Susan Bullman | Broad Institute of Harvard and MIT

Tools & Technologies
Moderator
Neelendu Dey | Fred Hutch

Minimizing Variability and Enhancing Accuracy in Microbiome Studies
Sujatha Srinivasan | Fred Hutch

Discovering Ultrasmall Bacteria and Homeostatic Mechanisms Through Cultivation of a High Diversity Oral Community In Vitro
Jeffrey Scott McLean | University of Washington

Analytics
Moderator
Sujatha Srinivasan | Fred Hutch

A Compositional Transform Reveals HIV Exposure Induced Shifts in the Fecal Microbiota and Vaccine Responsiveness of Nigerian Infants
Bryan Brown | Seattle Children’s Research Institute

Bacterial Genome Islands in the Gut Microbiome are Reproducibly Associated with Human Health and Disease
Sam Minot | Fred Hutch

Modeling and Testing the Human Microbiome in Longitudinal Perturbation Experiments
Susan Holmes | Stanford University

Microbiomes in the Context of Personal, Dense, Dynamic Data Clouds for Human Health
Nathan Price | Institute for Systems Biology; University of Washington; Arivale

Joint Analysis of Microbiome and Other Omic Data Types
Michael Wu | Fred Hutch; University of Washington

Our 2nd Symposium on Infectious Diseases in the Immunocompromised Host grew to a 2-day event with an expanded audience, increased trainee participation, and a broader range of critically relevant topics. More than 30 esteemed speakers provided their expertise as leaders in the field and gave our audience a chance to celebrate significant accomplishments in the field of infectious disease in the immunocompromised host. Forty-eight trainees were able to attend the symposium as part of our expanded travel stipend program.

Day 1 Introduction
Michael Boeckh | Fred Hutch; University of Washington

Keynote Address
Vaccine and Monoclonal Antibodies for CMV Prevention in Transplant Recipients
Paul Griffiths | University College London Medical School

Vaccines and Immunotherapy
Chair
Lawrence Corey | Fred Hutch; University of Washington

Immunologic Control of CMV in Transplantation
John Zaia | City of Hope National Medical Center

Adoptive T Cell Therapy for Viral Infections
Ann Leen | Baylor College of Medicine

Infections Following CAR T Cell Therapy
Joshua Hill | Fred Hutch; University of Washington

Fungal Infections
Chair
Kieren Marr | Johns Hopkins University School of Medicine

Candida Infections in the Immunocompromised Host
William Steinbach | Duke University Medical Center

Genetic Susceptibility for Invasive Aspergillosis
Tobias Hohl | Memorial Sloan Kettering Cancer Center

Novel Diagnostic Approaches to the Diagnosis of Invasive Aspergillosis
Sophia Koo | Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School

Pro/Con Debate: Upfront Combination Antifungal Therapy
Moderators:

• Catherine Liu | Fred Hutch; University of Washington; Seattle Cancer Care Alliance
• Joshua Schiffer | Fred Hutch; University of Washington

Debators:

• Dimitrios Kontoyiannis | The University of Texas MD Anderson Cancer Center
• Kieren Marr | Johns Hopkins University School of Medicine

Microbiome
Chair
David N. Fredricks | Fred Hutch; University of Washington

Microbiome in Transplantation
Ying Taur | Memorial Sloan Kettering Cancer Center

Gut Microbiome and GVHD
Jonathan Golob | Fred Hutch; University of Washington

Microbiome in Idiopathic Syndromes after Transplantation
Ami Bhatt | Stanford University School of Medicine

Lung Microbiome in Lung Transplantation
Ronald Collman | University of Pennsylvania School of Medicine

From Adenovirus to Zika
Chair
Steven Pergam | Fred Hutch; University of Washington; Seattle Cancer Care Alliance

Adenovirus Impact and Therapeutic Options
Janet Englund | Seattle Children's Hospital; University of Washington

HIV Infection and Transplantation
Christine Durand | Johns Hopkins School of Medicine

Zika Virus Infections in Immunocompromised Patients
Clarisse Machado | Universidade de São Paulo, Brazil

Respiratory Viruses
Chairs:

• Janet A. Englund | Seattle Children’s Hospital; University of Washington; Fred Hutch
• Per Ljungman | Karolinska University Hospital; Karolinska Institutet, Stockholm, Sweden

RSV and Parainfluenzavirus Infections in HCT Recipients
Roy Chemaly | The University of Texas MD Anderson Cancer Center

Rhinovirus in HCT Recipients
Alpana Waghmare | Seattle Children's Hospital; University of Washington; Fred Hutch

Respiratory Virus Infections in SOT Recipients
Deepali Kumar | University of Toronto

Respiratory Virus Infections in Chronic Allograft Dysfunction
Ajit Limaye | University of Washington

Panel Discussion: Challenges in Identifying Novel Clinical Endpoints for the Development of Therapeutics for Respiratory Virus infections in Immunocompromised Patients
Moderator
Per Ljungman | Karolinska University Hospital; Karolinska Institutet
Panelists:

• Roy Chemaly | The University of Texas MD Anderson Cancer Center
• Francisco Marty | Brigham and Women's Hospital; Dana-Farber Cancer Institute; Harvard Medical School
• Michael Boeckh | Fred Hutch; University of Washington
• Kieren Marr | Johns Hopkins University School of Medicine

Original Short Presentations By Trainees
Chairs:

• Julie McElrath, Fred Hutch; University of Washington
• Anna Wald, University of Washington; Fred Hutch

Therapeutic Drug Monitoring of Novel Formulations of Posaconazole in SOT Recipients
Ghady Haidar | University of Pittsburgh Medical Center

Performance of Targeted Fungal Sequencing for Culture-Independent Diagnosis of Invasive Fungal Disease
Carlos A. Gomez | Stanford University School of Medicine

Adoptive T Cell Therapy For HIV
Shabnum Patel | The George Washington University

Characterizing Monoclonal Antibodies Against Carbapenem-Resistant Klebsiella Pneumoniae
Elizabeth Diago-Navarro | Stony Brook University

Clinical Experience with Novel Cephalosporin/Beta-Lactamase Inhibitor Combinations in Solid Organ Transplant Recipients
Puja Nambiar | Cleveland Clinic

Chronic High EBV Load and T Cell Exhaustion in Pediatric Solid Organ Transplantation
Masaki Yamada | Children’s Hospital Pittsburgh

Cytomegalovirus
Chairs:

• Michael Boeckh | Fred Hutch; University of Washington
• Ajit Limaye | University of Washington; Fred Hutch

Prevention of CMV in SOT Recipients
Deepali Kumar | University of Toronto

Multivirus Infections
Joshua Schiffer | Fred Hutch; University of Washington

Antivirals to Prevent CMV in HCT
Francisco Marty | Brigham and Women's Hospital; Dana-Farber Cancer Institute; Harvard Medical School

Closing Remarks and Conclusion
Michael Boeckh | Fred Hutch; University of Washington

On June 13, 2016 Fred Hutch celebrated 25 years of achievements of the Joel Meyers Infectious Disease Endowment Scholarship with our first Symposium on Infectious Disease in the Immunocompromised Host. This special reunion honored Dr. Joel Meyers' legacy as an iconic leader in research and clinical care of infections in the immunocompromised patient. More than 140 attended the symposium to hear the latest in infectious disease research and network with colleagues.

Introduction
Larry Corey | Fred Hutch

Infection in the Immunocompromised Host: Where We Started and Where We Are Now
Phillip Pizzo | Stanford University

Introducing Antivirals at the Fred Hutch: The Early Days
James Wade | Inova Dwight and Martha Schar Cancer Institute

CMV Infection Prevention: Reflection and Forecast
John Zaia | City of Hope National Medical Center

Clostridium Difficile in Immunocompromised Patients: A Hospital Epidemiologist's View
Lucy Tompkins | Stanford University

Advances in Fungal Prophylaxis and Therapy in the Immunocompromised Host
Kieren Marr | Johns Hopkins University

Respiratory Virus Infections in the HCT Patient: Then and Now
Per Ljungman | Karolinska University Hospital, Karolinska Institute

Development of Antiviral Agents for DNA Viruses
W. Garrett Nichols | Chimerix, Inc.

The Human Microbiome
David Fredricks | Fred Hutch

Short talks by Joel Meyers scholars:

• Microbiome and HCT Outcomes
  Jonathan Golob | Fred Hutch (newly selected JM scholar)
• HHV-6 Infection in HCT Patients
  Joshua Hill | Fred Hutch
• Emerging Respiratory Virus Infections in HCT Patients
  Angela Campbell | Centers for Disease Control and Prevention
• IL-6 in Castleman Disease
  Corey Casper | Fred Hutch

Hepatitis C: A Model for Modern Viral Chemotherapy
M. Michelle Berrey | Chimerix, Inc.

Immunotherapy of Infectious Diseases
Stanley Riddell | Fred Hutch

ID in Immunocompromised Host: Future Challenges
Michael Boeckh | Fred Hutch